poly(ADP-ribose) polymerase family member 9Genealiases: ARTD9 · BAL · BAL1 · MGC:7868
Q-omics provides the consensus-scored PARP9 profile across patient tissues and cancer cell-line models. PARP9 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PARP9 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, PARP9 RNA expression shows 19,232 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, BLCA, and UVM as cancer lineages where PARP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARP9 survival associations across molecular data types. PARP9 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARP9 RNA expression–survival associations across cancer types. High PARP9 expression shows unfavorable associations in LGG, PAAD, UCEC and LUAD, but favorable associations in SKCM and ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PARP9 RNA expression.
This table summarizes PARP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PARP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARP9 shows higher tumor expression in BLCA, HNSC, KIRC, BRCA, STAD and THCA. The BLCA box plot shows higher PARP9 RNA expression in tumor versus normal tissue (log2 FC = +1.232, t-test p < 0.001).
This table shows molecular features associated with PARP9 in patient tissues and cancer cell lines. In patient samples, PARP9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PARP9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
